| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 08/23/2005 | US6933114 Nucleotide sequence ligand for use in the detection diagnosis and treatment of cancer |
| 08/23/2005 | US6933113 Modulation of endogenous gene expression in cells |
| 08/23/2005 | US6932960 Complexes with radionuclides; for use as contrast agent in magnetic resonance imaging (MRI); as parasiticide, viricide, or as chelation therapy of iron overload such as thalassemia; optimal combination of lipophilicity and hydrophilicity |
| 08/23/2005 | CA2267661C Variants of vascular endothelial cell growth factor having antagonistic properties |
| 08/23/2005 | CA2223469C Use of dopamine receptor antagonists in palliative tumour therapy |
| 08/23/2005 | CA2162761C Antineoplastic cyclolignan derivatives |
| 08/23/2005 | CA2153235C Compounds having selectivity for retinoid x receptors |
| 08/23/2005 | CA2111571C Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides |
| 08/23/2005 | CA2089442C Amino-substituted benzoylguanidines, process for their preparation, their use as a medicament and medicament containing them |
| 08/18/2005 | WO2005074991A1 Antitumor agent |
| 08/18/2005 | WO2005074968A2 Medical use of basic peptides |
| 08/18/2005 | WO2005074907A1 Gene expression controlling agent |
| 08/18/2005 | WO2005074896A1 Sustained release preparation |
| 08/18/2005 | WO2005035003A3 Compositions and methods for increasing drug efficiency |
| 08/18/2005 | WO2005026741A3 Non-peptide agonists and antagonists of adrenomedullin and gastrin releasing peptide |
| 08/18/2005 | WO2005021547A3 Heterocyclic cannabinoid cb2 receptor antagonists |
| 08/18/2005 | WO2005013899A3 Compositions and methods for the therapy and diagnosis of lung cancer |
| 08/18/2005 | WO2004100873A3 Compounds, compositions, and methods |
| 08/18/2005 | WO2004091490A3 Somatostatin-dopamine chimeric analogs |
| 08/18/2005 | WO2004083365A3 Compounds and their use for specific and simultaneous inhibition of genes involved in diseases and related drugs |
| 08/18/2005 | WO2004060890A8 2-oxopyridin-3-yl thia (di) azole derivates for use in the treatment of cell proliferation and apoptosis related diseases |
| 08/18/2005 | WO2004054516A3 Antagonists for human prolactin |
| 08/18/2005 | WO2003004608A3 Drug metabolizing enzymes |
| 08/18/2005 | WO2002099049A3 Tbc1d1s as modifiers of the p53 pathway and methods of use |
| 08/18/2005 | US20050182276 Process for the synthesis and crystalline form of agomelatine |
| 08/18/2005 | US20050182256 1-{1-[4-(6-hydroxy-5-isobutyl-3-phenylpyrazin-2-yl)benzyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one; antiproliferative |
| 08/18/2005 | US20050182130 Derivatives of dioxane-2-alkyl carbamates, preparation thereof and application thereof in therapeutics |
| 08/18/2005 | US20050182128 For preventing or reducing dysplastic lesions |
| 08/18/2005 | US20050182119 Anticancer agents; e.g. 1-(4-aminosulfonylphenyl)-3-trifluoromethyl-5-(2,5-dimethylphenyl)-4,5-dihydropyrazole or 1-(4-aminosulfonylphenyl)-3-trifluoromethyl-5-[3,5-di(trifluoromethyl)phenyl]-4,5-dihydropyrazole; improved antitumor activity; colon cancer, bowel cancer, or prostate cancer |
| 08/18/2005 | US20050182098 Administering taxanes having a carbamoyloxy substituent at C(10), a hydroxy substituent at C(7), and a range of C(2), C(9), C(14), and side chain substitutions for inhibiting tumor growth |
| 08/18/2005 | US20050182077 8-amino-7-substituted-2,6-dioxo-1,2,3,6-tetrahydro-7H-purines; erectile dysfunction; sexual disorders; psychological disorders; hypotensive agents; restenosis; cardiovascular disorders; antidiabetic agents; vision defects; autoimmune diseases; anticancer agents |
| 08/18/2005 | US20050182064 Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy |
| 08/18/2005 | US20050182057 Aryl N-cyanoguanidines and methods related thereto |
| 08/18/2005 | US20050182054 Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases |
| 08/18/2005 | US20050182042 Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic |
| 08/18/2005 | US20050182040 Benzamide derivatives |
| 08/18/2005 | US20050182035 cyclohexane ring is 3,5-dihydroxy-substituted and 2,4-alkylene-bridged; treating metabolic bone disease, cancer, skin disorders, immune system disorders, asthma, hypertension, hypothyroidism, hypocalcemia, female infertility and alopecia |
| 08/18/2005 | US20050182034 Method of locking 1alpha-OH of vitamin D compounds in axial orientation |
| 08/18/2005 | US20050182030 Antitumor, anticancer agents; osteoporosis; bone disorders; Paget's disorders; solution is provided in a sealed non-reactive plastic container of polypropylene, ABS, polyethylene, PVC, polycycloolefin; injectable, sterile, ready to use, pyrogen-free solution |
| 08/18/2005 | US20050182027 radiolabeled phosphonium or ammonium salts that accumulate in mitochondria of cancer cells; cancer diagnosis; tomography; distinguishes between tissue inflammation and tumors; e.g. F18-3-fluoropropyltriphenyl phosphonium bromide |
| 08/18/2005 | US20050182019 Phosphonate compounds |
| 08/18/2005 | US20050182017 Immunostimulatory nucleic acid molecules |
| 08/18/2005 | US20050182002 Killing Burkitt's lymphoma cell or a chronic lymphocytic leukaemia cell |
| 08/18/2005 | US20050181995 Venom-derived vascular endothelial growth factor-like protein having binding activity specific to vascular endothelial growth factor receptor type 2 and use thereof |
| 08/18/2005 | US20050181972 Modification of the properties of a fibrin matrix with respect to growth and ingrowth of cells |
| 08/18/2005 | US20050181506 Chromosome-based platforms |
| 08/18/2005 | US20050181501 Anti-TECK antibodies and methods of use therefor |
| 08/18/2005 | US20050181462 Mutant androgen receptor, cancer cells expressing the same, a method of producing them and use thereof |
| 08/18/2005 | US20050181448 Biological products |
| 08/18/2005 | US20050181418 Using nuclear protein (AM-1) as screening tool in diagnosing metastatic cancer |
| 08/18/2005 | US20050181414 Peptides associated with serine protease active site for use in identification of modulators for treatment of cell proliferative disorders |
| 08/18/2005 | US20050181413 Ovarian specific nucleic acid (OSNA) for use as diagnostic and prognostic tools in treatment and prevention of urogenital cancers; genetic vaccines |
| 08/18/2005 | US20050181391 Method of detecting and treating tuberous sclerosis complex associated disorders |
| 08/18/2005 | US20050181368 Protein for use in hypoxia related conditions |
| 08/18/2005 | US20050181362 Aligning the test nuclear receptor (NR) polypeptide, with at least one reference NR polypeptide sequence for which an X-ray structure is available; building a three-dimensional model for the test NR polypeptide, examining the three-dimensional model of the test NR polypeptide sequence for difference |
| 08/18/2005 | US20050181064 Drugs comprising protein forming hollow nanoparticles and therapeutic substance to be transferred into cells fused therewith |
| 08/18/2005 | US20050181038 Novel method of stabilizing diagnostic and therapeutic compounds in a cationic carrier system |
| 08/18/2005 | US20050181034 3-Amidino- or 3-guanidino phenylalanine derivative which is effective as urokinase inhibitor; antitumor, anticarcinogenic, and antimetastasis agents |
| 08/18/2005 | US20050180985 Live attenuated salmonella strains for producing monovalent or multivalent vaccines |
| 08/18/2005 | US20050180982 Assessing metastatic potential of carcinoma cells by contacting cells in tissue sample suspected of containing carcinoma with detectable indicator capable of binding to cad-11 or cad-11 mRNA and determining presence or absence of cad-11 expression in tissue; method of preventing or terminating pregnancy |
| 08/18/2005 | US20050180981 Human checkpoint kinase, hCDS1, compositions and methods |
| 08/18/2005 | US20050180975 Combined use of anti-cytokine antibodies or antagonists and anti-CD20 for treatment of B cell lymphoma |
| 08/18/2005 | US20050180971 Cancer therapy |
| 08/18/2005 | US20050180960 producer cell (encapsulated in a matrix containing immunostimulating alginates) expresses a molecule that is an inhibitor of the growth of a CNS tumor |
| 08/18/2005 | US20050180959 Kinases involved in the regulation of energy homeostasis |
| 08/18/2005 | US20050180953 peptides derivatives as an agent inducing cells differentiation and in particular, to their use in antitumor noncytotoxic therapy; melanoma; most preferred compound used in the present invention is 4-[N-(2-imidazol-4-yl)ethyl)carbamoyl]butyric acid (Dicarbamine (reg) ) |
| 08/18/2005 | US20050180946 such as triethanolamine with 2 hydroxyethyl groups derivatized with polyethylene glycol, and the amine group conjugated to drugs such as antitumor agent interferon |
| 08/18/2005 | US20050180917 Delivery of neutron capture elements for neutron capture therapy |
| 08/18/2005 | DE102004004974A1 Thieno-Iminosäure-Derivate als Inhibitoren von Matrix-Metalloproteinasen Thieno-imino acid derivatives as inhibitors of matrix metalloproteinases |
| 08/18/2005 | DE102004004787A1 New effector-linker and effector-recognition unit conjugates derived from epothilones, useful as targeted drugs for treating proliferative diseases, e.g. tumors or neurodegenerative disease |
| 08/18/2005 | DE102004003801A1 Recovering melanin from plant materials, for use e.g. in cancer treatment or as semiconductor, by extracting with sodium hydroxide solution, acidifying extract and purifying precipitate |
| 08/18/2005 | DE10134196B4 Pharmazeutische Zusammensetzung zur Hemmung der unkontrollierten Vermehrung und/oder Induzierung der Apoptose von Zellen A pharmaceutical composition for inhibiting uncontrolled proliferation and / or inducing apoptosis of cells |
| 08/18/2005 | DE10008159B4 Verwendung von 2-Methyl-thiazolidin-2,4-dicarbonsäure und/oder ihrer physiologisch verträglichen Salze als Antikrebsmittel Use of 2-methyl-thiazolidine-2,4-dicarboxylic acid and / or their physiologically acceptable salts as an anti-cancer agent |
| 08/18/2005 | CA2555306A1 Humanized antibody |
| 08/18/2005 | CA2555262A1 1h-thieno[2,3-c]pyrazole derivatives useful as kinase inhibitors |
| 08/18/2005 | CA2554683A1 Use of alkaline phosphatase for the detoxification of lps present at mucosal barriers |
| 08/18/2005 | CA2554262A1 Sustained-release preparations |
| 08/18/2005 | CA2553899A1 Chemically-modified human growth hormone receptor antagonist conjugates |
| 08/18/2005 | CA2553887A1 Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide |
| 08/18/2005 | CA2552937A1 Combination of (a) a dna topoisomerase inhibitor and (b) an iap inhibitor |
| 08/17/2005 | EP1564292A1 Pharmaceutical compositions and methods of treatment based on VEGF antisense oligonucleotides |
| 08/17/2005 | EP1564219A1 N-terminally monopegylated polypeptides and process for their preparation |
| 08/17/2005 | EP1564202A1 Novel process for synthesizing and a novel crystal form of agomelatin as well as pharmaceutical preparations containing these |
| 08/17/2005 | EP1563847A1 Agent eleveting dendritic cell precursor level in blood |
| 08/17/2005 | EP1563836A1 Drug for inhibiting production of matrix metalloprotease-9 |
| 08/17/2005 | EP1563832A1 Liposome comprising a compound containing 2 polyalkylene glycol groups |
| 08/17/2005 | EP1563308A2 Methods and kits for diagnosing tumorigenicity |
| 08/17/2005 | EP1563307A1 Tumour marker proteins and uses thereof |
| 08/17/2005 | EP1562977A2 Active specific immunotherapy of cancer metastasis |
| 08/17/2005 | EP1562955A1 Quinazoline derivatives as src tyrosine kinase inhibitors |
| 08/17/2005 | EP1562951A2 Porphyrin derivatives |
| 08/17/2005 | EP1562947A1 4-amino-5-phenyl-7-cyclohexyl-pyrrolo[2,3-d]pyrimidine derivatives |
| 08/17/2005 | EP1562939A1 Carboxamides |
| 08/17/2005 | EP1562933A2 Substituted amine derivatives and methods of use in the treatment of angiogenesis related disorders |
| 08/17/2005 | EP1562928A1 Aromatic sulfone hydroxamic acids and their use as protease inhibitors |
| 08/17/2005 | EP1562920A1 Antiinflammatory 3-arylthio-3-thiazolyl-alkylamines |
| 08/17/2005 | EP1562906A2 Heterocyclic selective androgen receptor modulators and methods of use thereof |
| 08/17/2005 | EP1562620A2 Modified cytokines for use in cancer therapy |
| 08/17/2005 | EP1562616A2 Formulation of oral compositions comprising arsenic trioxide and methods of use thereof |
| 08/17/2005 | EP1562612A1 Combination product of inhibitor of the src family of non-receptor tyrosine kinases and gemcitabine |